HONG KONG -- China is set this year to become the second-largest market in the world for the group of American-owned companies that make OxyContin, the painkiller blamed for setting off a deadly opioid epidemic in the U.S.
"This is where the growth is coming from," Raman Singh, chief executive of Singapore-based Mundipharma, which handles the group's sales of prescription drugs outside of Europe and North America, told the Nikkei Asian Review in Hong Kong. "By 2025, I'm hoping [China] will become the [group's] largest market, overtaking the U.S."
